☆ 4.7 Letter

Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19

ANNALS OF THE RHEUMATIC DISEASES (2020)

Get Full Text
Add to Collection

Journal

ANNALS OF THE RHEUMATIC DISEASES
Volume 79, Issue 10, Pages 1386-1388

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2020-217690

Keywords

lupus erythematosus; systemic; hydroxychloroquine; epidemiology; pharmacokinetics

Categories

Rheumatology

Funding

  1. National Institute for Health Research University College London Hospitals Biomedical Research Centre

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.